Results 31 to 40 of about 64,981 (166)

Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies

Frontiers in Immunology, 2022
Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients.
Jennifer R. Blase, David Frame, Thomas F. Michniacki, Kelly Walkovich   +3 more
doaj   +1 more source

Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis

BMC Neurology
Objective This meta-analysis synthesizes evidence from all available randomized trials and observational cohort studies evaluating the efficacy and safety of ocrelizumab compared to placebo or active comparator therapies.
Adil Nawaz, Arsalan Bakhtiyar, Muhammad Ibrahim Khan, Erum Siddiqui, Elsa Khan, Muhammad Abbas, Muhammad Saad, Muhammad Qasim, Muhammad Taha   +8 more
doaj   +1 more source

γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody

Haematologica, 2011
Background Anti-CD20 monoclonal antibodies are major therapeutic agents for patients with follicular lymphoma and work through complement-mediated cytotoxicity and antibody-dependent cellular cytotoxicity.
Mounia Sabrina Braza, Bernard Klein, Geneviève Fiol, Jean-François Rossi   +3 more
doaj   +1 more source

A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms

Frontiers in Molecular Biosciences, 2020
As human Tau undergoes pathologically relevant post-translational modifications when expressed in yeast, the use of humanized yeast models for the generation of novel Tau monoclonal antibodies has previously been proven to be successful.
Joke Verelst, Nick Geukens, Sabiha Eddarkaoui, Dorien Vliegen, Elien De Smidt, Joëlle Rosseels, Vanessa Franssens, Sofie Molenberghs, Cindy Francois, Erik Stoops, Maria Bjerke, Maria Bjerke, Sebastiaan Engelborghs, Sebastiaan Engelborghs, Mohamed Laghmouchi, Sofie Carmans, Luc Buée, Eugeen Vanmechelen, Joris Winderickx, Debby Thomas   +19 more
doaj   +1 more source

A rare adverse effect in inebilizumab therapy for neuromyelitis optica spectrum disorder: a case report

Therapeutic Advances in Neurological Disorders
Inebilizumab is one of the monoclonal antibodies approved as maintenance therapy for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (NMOSD).
Xuefen Chen, Ziyan Shi, Rui Wang, Hongyu Zhou   +3 more
doaj   +1 more source

Dupilumab for recalcitrant prurigo nodularis: Case report

Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
Dupilumab is a recombinant fully human monoclonal antibody modulating the signaling of the interleukin (IL)—4 and IL-13 pathways and has been approved for the treatment of moderate/severe atopic dermatitis.
Joel Reis, Inês Raposo, Manuela Selores
doaj  

Recent Advances in the Development of Vaccines for Diabetes, Hypertension, and Atherosclerosis

Journal of Diabetes Research, 2018
Vaccines are commonly used in the prevention of infectious diseases. The basic principle of vaccination is to use specific antigens, endogenous or exogenous to stimulate immunity against the specific antigens or cells producing them. Autoantigen or oligo
Kongye Lu, Benli Su, Xiuxiang Meng
doaj   +1 more source

Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD)

Human Vaccines & Immunotherapeutics, 2018
Pandemic outbreaks of influenza type A viruses have resulted in numerous fatalities around the globe. Since the conventional influenza vaccines (CIV) provide less than 20% protection for individuals with weak immune system, it has been considered that ...
Mirian Mendoza, Angela Ballesteros, Qi Qiu, Luis Pow Sang, Soumya Shashikumar, Sofia Casares, Teodor-D. Brumeanu   +6 more
doaj   +1 more source

ANTISENSE OLIGONUCLEOTIDES AND THERAPEUTICAL MONOCLONAL ANTIBODIES AS A BASEMENT FOR NOVEL BIOLOGICAL LIPIDLOWERING DRUGS

Российский кардиологический журнал, 2018
Development of innovational biotechnological medications based on humanized or completely human monoclonal antibodies or antisense oligonucleotides has opened a novel epoque in lipid disorders treatment. High efficacy of such biological drugs influencing
O. I. Afanasieva, M. V. Ezhov, S. N. Pokrovsky   +2 more
doaj   +1 more source

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Lung Cancer: Targets and Therapy, 2011
Masayuki Takeda1, Isamu Okamoto1, Yasumasa Nishimura2, Kazuhiko Nakagawa11Department of Medical Oncology, 2Department of Radiation Oncology, Kinki University Faculty of Medicine, Osaka, JapanAbstract: The epidermal growth factor receptor (EGFR) is a ...
Takeda M, Okamoto I, Nishimura Y, Nakagawa K   +3 more
doaj